Andrew is a senior M&A and equity capital markets lawyer with extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings, joint ventures and private financing rounds.

He is one of only six London lawyers to be ranked in Tier 1 for mid-market M&A by Chambers UK legal directory as well as being listed as one of The Lawyer's Hot 100. As quoted in the legal directories, Andrew's clients describe him as 'a strong negotiator and problem solver' as well as being 'Incredibly pragmatic. The perfect sounding board for our business.'

Andrew is the UK Head of Corporate Life Sciences and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries.

While at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

Afficher le CV complet Masquer le CV complet

Actualités et publications récentes

Sciences de la vie et Santé

Shield Therapeutics enters transformational collaboration agreement with Viatris and raises debt and equity finance

6 janvier 2023

par Andrew Edge

Cliquer ici pour en savoir plus

Recognition for our expertise as Life Sciences Team of the Year

24 novembre 2022

par plusieurs auteurs

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Aspen Healthcare sold to Canadian-based property trust

27 septembre 2021

par Andrew McLean et Andrew Edge

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Advising Apollo Therapeutics on $145 million financing

21 juin 2021

par Andrew Edge et Chris Cowley

Cliquer ici pour en savoir plus

Autres avocats qui pourraient vous intéresser